sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY March 2016 | Archived Issues

P & T Approvals; FDA Warns About Zydelig

Pharmacy Focus

See highlights of the February meeting of the Pharmacy and Therapeutics Committee. Also, the U.S. Food and Drug Administration is alerting healthcare professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig in combination with other cancer medicines.


Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Education Schedule

Click the PDF link below to see the Department of Surgery's education schedule.

Education Schedule - March 2016  


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

P & T Approvals; FDA Warns About Zydelig

Pharmacy Focus

Highlights of the February meeting of the Pharmacy and Therapeutics Committee are summarized in the PDF link below.

P & T Approvals - February 2016 (PDF)  

FDA: Adverse Events Increase When Zydelig Combines With Other Cancer Drugs

The U.S. Food and Drug Administration is alerting healthcare professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig in combination with other cancer medicines.

The drug's maker, Gilead Sciences Inc., has confirmed that it is stopping six clinical trials in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and indolent non-Hodgkin lymphomas.

Healthcare professionals should be aware that Zydelig (idelalisib) is not approved for previously untreated chronic lymphocytic leukemia.

Zydelig is currently approved by the FDA for the treatment of:

  • Relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities
  • Relapsed follicular B-cell non-Hodgkin lymphoma in patients who have received at least two prior systemic therapies
  • Relapsed small lymphocytic lymphoma in patients who have received at least two prior systemic therapies

The FDA has more information.